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Short running title: Recommendations for PET Imaging in Gliomas  
This work has not been funded. 
 
ABSTRACT 
This guideline provides recommendations for the use of positron emission 
tomography (PET) imaging in gliomas. The review examines established clinical 
benefit in glioma patients of PET using glucose (18F-FDG) and amino acid tracers 
(11C-MET, 18F-FET and 18F-FDOPA). An increasing number of studies have been 
published on PET imaging in the setting of diagnosis, biopsy and resection as well 
radiotherapy planning, treatment monitoring and response assessment. 
Recommendations are based on evidence generated from studies which validated 
PET findings by histology or clinical course.  This guideline emphasizes the clinical 
value of PET imaging with superiority of amino acid PET over glucose PET and 
provides a framework for the use of PET to assist in the management of patients with 
gliomas.  
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INTRODUCTION 
Gliomas are the second most common primary brain tumors with an incidence of 4-5 
/100,000 individuals. Gliomas are the second leading cause of cancer mortality in 
adults under the age of 35, the fourth leading cause in those under the age of 54, 
and result in death in approximately 13,770 individuals per year in the United States 
(US) 1. Median survival of glioblastoma, the most aggressive variant, is 16 months in 
patients treated with maximum safe resection, radiotherapy and concurrent and 
adjuvant temozolomide in clinical trial populations 2-4.  
Magnetic resonance imaging (MRI) is the mainstay of imaging of gliomas both to 
monitor treatment and response. T1-weighted MRI without and with contrast medium, 
T2-weighted as well as fluid-attenuated inversion recovery (FLAIR) MRI sequences 
are used for anatomic imaging. However, many brain tumors (particularly WHO grade 
II and a significant number of WHO grade III gliomas) do not enhance with contrast-
agent administration, reducing the ability of contrast imaging to accurately quantify 
tumor burden. The challenge to accurately determine brain tumor response by MRI  
both in daily practice and in clinical trials has led to the introduction of updated 
guidelines by the Response Assessment in Neuro-Oncology (RANO) working group 
5.  
Functional molecular imaging such as positron emission tomography (PET) uses 
various tracers to visualize biological processes such as cell proliferation, membrane 
biosynthesis, glucose consumption and uptake of amino acid analogs 6. Hence, PET 
provides additional insight beyond MRI into the biology and treatment response of 
gliomas which may be used for non-invasive grading, differential diagnosis, 
delineation of tumor extent, surgical and radiotherapy treatment planning, post-
treatment surveillance and prognostication. 
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Analogous to the RANO effort regarding MRI use in gliomas, an initiative was 
undertaken by a group of clinicians and nuclear medicine physicians to similarly 
define standards of molecular imaging for gliomas using PET with respect to 
interpretation and validation as well as to define its role in clinical practice. In this 
paper, evidence-based recommendations are proposed for the use of PET imaging in 
the clinical management of glioma patients. Accordingly, the review discusses tracers 
which image glucose metabolism (18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and 
amino acid transport ([11C-methyl]-methionine (11C-MET), O-(2-[18F]-fluoroethyl)-L-
tyrosine (18F-FET) and 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-FDOPA)) 
since these compounds have already entered clinical practice.  
The current guidelines aim to serve medical professionals of all disciplines involved in 
the diagnosis and care of patients with gliomas. A separate procedural guideline 
focusing on the standardization of technical aspects of PET imaging for glioma will be 
the subject of another manuscript prepared by the EANM (Euopean Association of 
Nuclear Medicine) / EANO (Euopean Association of Neuro-Oncology)  / RANO 
groups. 
 
LEVELS OF VALIDATION AND CLINICAL EVIDENCE - Search strategy and 
selection criteria 
The information retrieved from a PubMed search  of the published literature with the 
combination of the following search terms “glioma”, “glioblastoma”, “brain tumor”, 
“PET”, “FDG”, “FET”, “MET” and “DOPA” until September, 2015 as well as from 
articles identified through searches of the authors’ own files was evaluated by the 
working group with respect to the level of evidence and the grade of validation of the 
PET studies examined. 
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Any study that correlated the PET findings with histopathology was considered to 
represent the highest degree of validation. Next, correlation with MRI (when 
applicable, according to RANO criteria) and with the patient’s clinical course was 
used for the second level of validation. Only papers constituting level 1-3 evidence 
according to Oxford Centre for Evidence-based Medicine (OCEBM Levels of 
Evidence Working Group: "The Oxford 2011 Levels of Evidence") were included.  
 
GENERAL RECOMMENDATIONS  
Recommendations for clinical use and diagnostic performance of differing PET 
tracers compared to MRI are presented in Tables 1 and 2 and in Fig. 1. 
 
 
 
SPECIFIC RECOMMENDATIONS 
 
Primary Diagnosis / Differential Diagnosis 
18F-FDG PET may provide useful information for distinguishing gliomas from other 
malignant brain tumors, but its specificity is limited. Importantly maximum 
standardized uptake values (SUVmax) were significantly higher in primary CNS 
lymphomas (PCNSL) than in glioblastoma 7, 8. However, corticosteroid medication 
may reduce uptake.  
The differential diagnosis by 18F-FDG PET between WHO grade III/IV gliomas and 
brain metastases is limited since considerable overlap of SUVmax exists between 
these tumor types 7. 18F-FDG PET also has limited specificity for distinguishing 
glioma from other non-neoplastic lesions, such as brain abscesses, demyelinating 
tumefactive (“tumor-like”) lesions, fungal infections, and neurosarcoidosis 9 due to 
increased 18F-FDG metabolism in inflammatory tissue.  
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Amino acid PET is useful for the non-invasive differentiation of tumor and non-
tumoral processes as tumors have significantly higher uptake than non-neoplastic 
tissue 10, 11. However, moderately increased uptake can also be seen in acute 
inflammatory lesions such as active multiple sclerosis or brain abscesses 12, 13. 
Conversely, lack of 18F-FET uptake does not exclude a glioma, as approximately one-
third of WHO grade II gliomas and most dysembryoplastic neuroepithelial tumors 
(DNET, WHO grade I) are 18F-FET-negative 14. However, among WHO grade III and 
IV gliomas, the vast majority (>95%) show increased uptake 11, 12, 15, with a resultant 
high sensitivity for the detection of these tumors. A recent meta-analysis revealed 
that for brain tumor diagnosis 18F-FET PET performed much better than 18F-FDG 
PET and consequently would be the preferred PET tracer when assessing patients 
with a newly diagnosed brain tumor 16. Furthermore, numerous studies validated by 
histology have demonstrated higher diagnostic accuracy of additional amino acid 
PET compared to anatomic MRI alone for the differentiation of gliomas from non-
neoplastic lesions 12 11, 17-19.   
 
 In cases of diagnostic uncertainty, amino acid PET improves sensitivity, 
specificity and accuracy and is markedly superior to 18F-FDG PET in 
differentiating between glioma and non-neoplastic tissue  
 
Tumor Grading 
The value of 18F-FDG PET for grading of gliomas is hampered by the poor tumor-to-
background contrast due to physiologically increased glucose uptake of cortical and 
subcortical (basal ganglia, thalamus) structures in brain and high variation of uptake 
and overlap of uptake values between tumors of different WHO grades, especially in 
oligodendroglial tumors 20, 21. However, WHO grade III and IV gliomas generally have 
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higher 18F-FDG values than WHO grade II gliomas, which often appear as a 
hypometabolic lesion, particularly when compared to the uptake in the cortex 16.  
Characteristically, amino acid uptake is higher in gliomas of WHO grade III/IV 
compared to WHO grade II gliomas. However, uptake intensities may vary, and 
tumor-to-brain ratios show a considerable overlap between different WHO grades as 
well as histological subtypes 11, 12, 22-24. For 18F-FET, accuracy for tumor grading can 
be markedly improved by evaluating dynamic (kinetic) PET data, which typically 
shows steadily increasing time-activity-curves in WHO grade II gliomas as opposed 
to an early activity peak around 10-20 minutes after injection, followed by a decrease 
of 18F-FET uptake in WHO grade III/IV gliomas 22, 25. This is particularly valuable in 
the clinical setting of patients with MRI non-contrast enhancing gliomas suspected of 
harboring a WHO grade II glioma. In approximately 40% of such cases an anaplastic 
focus is demonstrated 14, 26. In these patients, kinetic analysis provides a higher 
sensitivity and specificity for the detection of WHO grade III/IV gliomas (95%) 14. This 
method of kinetic analysis does not work for 11C-MET 24, and for 18F-FDOPA data are 
still controversial 27, 28.  
 Although 18F-FDG and amino acid uptake are usually higher in WHO 
grade III/IV gliomas than in WHO grade II gliomas, tumor grading is 
limited due to significant overlap in uptake values  
 Dynamic analysis of 18F-FET PET uptake further improves differential 
diagnosis between WHO grade II and WHO grade III/IV gliomas  
 
Delineation of Glioma Extent  
Multiple histopathological and postmortem series demonstrate the limitations of 
conventional MRI in defining the extent of glioma 29, 30. Moreover, the usefulness of 
18F-FDG PET in tumor delineation, given high uptake in normal brain cortex and low 
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uptake in gliomas WHO grade II, is particularly limited for cortical or pericortical 
tumors, even when dual-time-point images are performed 31. In contrast, amino acid 
PET imaging more accurately identifies infiltrating regions of tumor extending beyond 
the MRI contrast-enhancing lesion and often distinguishes between tumor, non-
tumoral edema and normal brain 32. In addition, amino acid PET provides functional 
and metabolic information about the tumor, and may identify tumor regions with 
different biological and clinical behavior. In both glioma WHO grade II and WHO 
grade III/IV gliomas, amino acid PET complements conventional MRI by providing 
additional information about tumor extent and biology.  
 
WHO grade III/IV gliomas 
Both the uptake and image contrast between tumor and normal tissue of amino acid 
tracers such as 11C-MET or 18F-FET are similar 33. PET-based tumor volumes have 
been shown to extend beyond the contrast-enhancing volume on conventional MRI 
by 2-3.5 cm for different tracers 34-37. In addition, amino acid PET identifies tumor 
extent within non-specific regions of T2/FLAIR signal abnormality 34, 36. 
 
WHO grade II glioma 
Most WHO grade II gliomas are non-enhancing with infiltrating tumor borders that are 
difficult to delineate by conventional MRI. Several studies have demonstrated the 
usefulness of amino acid PET in defining tumor extent. This has been demonstrated 
in histology-validated series for 11C-MET, 18F-FET and 18F-FDOPA PET 17, 38-41.  
 
 18F-FDG is not suitable for glioma volume delineation 
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 Delineation of tumor borders by amino acid PET is superior to standard 
MRI both in contrast-enhancing as well as non-contrast-enhancing 
gliomas 
 
Value for Treatment Planning: Biopsy and Resection  
Implementation of PET into biopsy and resection planning is advantageous, as PET 
better delineates tumor extent compared to standard MRI and additionally identifies 
intratumoral heterogeneity including malignant foci in non-contrast enhancing 
gliomas.  
Numerous studies have investigated the benefit of incorporating 18F-FDG or amino 
acid PET into biopsy target planning. The identification of malignant foci (“hot spots”) 
in MRI heterogeneous gliomas is essential for biopsy planning to ensure that the 
biologically most aggressive portion of the tumor, which determines the patient’s 
prognosis as well as treatment, is not undersampled 26, 42. There are several reports 
that illustrate the advantages of amino acid PET-based resection planning, of 
considerable importance whenever functional, eloquent areas may be involved 26, 34, 
43 and which demonstrate a higher probability of detecting more highly malignant 
areas within a MRI heterogeneous glioma as well as decreased risk of incomplete 
resection 44, 45 46. 
 Integration of amino acid PET into surgical planning allows better 
delineation of the extent of resection beyond margins visible with 
standard MRI. This is of considerable importance whenever functional 
eloquent areas of brain are involved  
 For biopsy planning, amino acid PET is particularly helpful in identifying 
malignant foci within non-contrast-enhancing gliomas 
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Value for Treatment Planning: Radiation 
Beyond MRI-based morphologic gross tumor volume (GTV) delineation, a biological 
tumor volume (BTV) may be defined by radiotracer uptake on amino acid PET that 
identifies tumor beyond the extent visible with standard MRI 47. In addition, the 
biologic and metabolic information provided by PET may identify subregions of tumor 
at higher risk of recurrence, which can be included in the radiation boost volume. The 
ability to better define tumor extent and biology may be used to improve the 
therapeutic ratio of radiation treatment. The current recommendations focus on the 
role of PET for radiation planning of WHO grade III/IV gliomas, as the role of PET 
imaging in irradiation of WHO grade II gliomas is not well-established. 
Small, prospective studies systematically comparing contrast MRI tumor volume (the 
“standard” radiation boost target) and 18F-FDG uptake abnormality generally 
demonstrate a smaller region of 18F-FDG uptake contained within the MRI 
abnormality, with only occasional extension outside of the MRI target 48, 49. Although 
small studies have demonstrated the feasibility of radiation boost planning using 18F-
FDG PET, its utility is limited by the low contrast between tumor and normal cortex 48.  
Studies analyzing patterns of failure following conventional chemoradiotherapy based 
on standard MRI-defined tumor volumes suggest that amino acid PET-defined tumor 
volumes may yield a more appropriate radiation target volume 50, 51, 52. In these small 
studies, a proportionate increase in marginal or non-central tumor recurrences were 
seen when regions of 11C-MET and 18F-FET abnormality were not adequately 
covered by high-dose radiation. Prospective, single arm studies evaluating the use of 
amino acid PET for radiation treatment planning of recurrent WHO grade III/IV glioma 
suggest the feasibility of this approach, and most studies suggest an improvement in 
outcome compared to radiation planning based on conventional MRI alone 53, 54. 
However, the inclusion of amino acid PET-based tumor volumes in standard-dose 
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radiation therapy and re-irradiation protocols continue to demonstrate a 
predominance of in-field tumor recurrences, highlighting the need for more effective 
therapies 55, 53, 54, 56.  
 Amino acid PET may improve the delineation of a biological tumor volume 
beyond conventional MRI, and identify aggressive tumor subregions that may 
be targeted by radiation therapy 
 While 18F-FDG PET is of limited utility in radiation treatment planning of WHO 
grade III/IV gliomas, radiation planning using amino acid PET appears feasible, 
with preliminary evidence of potential benefit 
 
 
Follow-up – Treatment Response, Progression, Pseudoprogression and 
Radionecrosis 
To date, standard, structural MRI is the most important diagnostic tool for assessing 
treatment effects in patients with gliomas 4. The extent of contrast enhancement on 
MRI is usually considered as an indicator of treatment response (e.g., Macdonald 
criteria, RANO criteria) 5, 57 although its reliability in distinguishing tumor tissue from 
treatment effects, which can include blood-brain barrier breakdown, is limited 58. For 
example, transient blood-brain barrier alteration with contrast enhancement – e.g. 
after radiotherapy with or without concomitant temozolomide - can mimic tumor 
progression and is termed pseudoprogression 59, 60. In addition, since the introduction 
of antiangiogenic agents such as bevacizumab the phenomenon of pseudoresponse 
complicates the assessment of treatment response using standard MRI alone  59, 61.  
WHO grade III/IV glioma 
Few 18F-FDG PET studies have measured the glucose metabolic rate following either 
radiotherapy, chemotherapy or both: decrease of 18F-FDG uptake correlates with 
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treatment response 62, 63, 64. 18F-FDG PET has been found to be of only moderate 
additional value to MRI for differentiation between malignant glioma recurrence and 
radionecrosis especially due to low specificity 65, 66 67 68. However, there are several 
limitations: most studies were retrospective, jointly assessed gliomas of all WHO 
grades, used differing treatments, had varying assessment strategies, and utilized 
varying 18F-FDG thresholds of tumor to normal brain for image interpretation.  
The feasibility and usefulness of amino acid PET such as 11C-MET, 18F-FET or 18F-
FDOPA PET for treatment assessment after chemoradiotherapy, stereotactic 
brachytherapy, chemotherapy and other experimental approaches have been 
demonstrated in several studies, primarily in WHO grade III/IV gliomas. Current 
amino acid PET data suggest that both a reduction of amino acid uptake and / or a 
decrease of the metabolically active tumor volume are a sign of treatment response 
associated with long-term outcome 69, 70, 71, 72, 73. Amino acid PET using 18F-FET may 
facilitate the diagnosis of pseudoprogression in glioblastoma patients within the first 
12 weeks following completion of chemoradiotherapy 74. 
Furthermore, several studies suggest that treatment response and outcome in 
bevacizumab therapy can be assessed by amino acid PET using 18F-FET and 18F-
FDOPA better than by MRI 75-78. 
Amino acid PET is useful for the differentiation between treatment related changes 
and true progression with high sensitivity and specificity 37, 79, 80. A combination of 
static and dynamic 18F-FET PET parameters identified correctly progressive or 
recurrent glioma with higher accuracy (93%) than conventional MRI 81. 
 
WHO grade II glioma 
In contrast to patients with gliomas WHO grade III/IV, the experience with amino 
acid PET for monitoring after treatment in patients with WHO grade II gliomas is 
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limited with only few studies available in the literature 82, 83. As these tumors are 
usually negative on 18FDG PET, the latter is not suitable for response evaluation. 
 Analysis of 18F-FDG uptake does not reliably distinguish between 
recurrence and radionecrosis 
 A decrease in amino acid uptake and/or volume is associated with 
treatment response across gliomas of WHO grade III-IV 
 Amino acid PET improves the assessment of pseudoprogression, 
radionecrosis and pseudoresponse 
 
Prognostication  
The prognostic value of 18F-FDG uptake in gliomas has been suggested by several 
studies 84-87. Additionally, pretreatment 18F-FDG PET has been reported to correlate 
with survival in patients with newly diagnosed glioblastoma 88 or recurrent high grade 
gliomas receiving bevacizumab 89. 
The prognostic value of amino acid PET has been increasingly explored 15, 90-92. At 
diagnosis, dynamic 18F-FET-PET identified highly aggressive astrocytomas within the 
same WHO grade – e.g., WHO grade II gliomas with decreasing time-activity-curves 
manifested earlier tumor progression, malignant transformation as well as shorter 
survival 91, 93. Similarly dynamic 18F-FET PET identified anaplastic astrocytomas with 
a very early decrease of time-activity-curves - and consequently short time-to-peak - 
as having a comparably poor outcome 15.  
To date, the association of glioma 18F-FET uptake with survival has remained 
controversial. Some groups have reported a better outcome of patients with absent or 
only low tumoral amino acid uptake 86, 90, 94. In contrast, another larger study of 18F-
FET-negative glioma patients did not reveal an association with improved outcome, 
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as neither time to transformation, which was proven upon histological evaluation, nor 
overall survival differed from FET-positive glioma patients 15.  
A prospective multicenter trial investigating the role of pre-treatment 18F-FET PET in 
newly diagnosed glioblastoma found biological tumor volume prior to 
chemoradiotherapy to be highly prognostic for outcome 46. This is in accordance with 
results of previous studies investigating amino acid PET in malignant glioma prior to 
therapy 69, 95. 
 Uptake of 18F-FDG and amino acid tracer is associated with outcome in 
glioma WHO grade III/IV both in a pre-treatment setting and following 
therapy 
 Biological tumor volume in amino acid PET is associated with survival 
following therapy in glioblastoma 
 Dynamic analysis of 18F-FET-uptake provides prognostic information 
within all grades of glioma prior to treatment 
 
Current limitations 
While 18F-FDG is used at all PET sites, only few centers offer amino acid PET so far. 
However, due to the 18F-labelling of FET and FDOPA, the radiotracer can be 
delivered in the same way as 18F-FDG, facilitating the availability of amino acid PET. 
Only for 11C-MET an on-site cyclotrone is required. The major obstacle for the 
widespread use of amino acid PET in glioma patients is to date the limited 
reimbursement by health insurance companies / institutions, despite the fact that 
current data clearly favour amino acid over 18F-FDG PET. 
Across all tracers, numerous studies differed in terms of methodology, which limits 
comparability of data and might eventually jeopardize acceptance in the clinical 
N-O-D-16-00028R1 
 
15 
 
setting. However, this guideline collected convincing support that PET imaging is of 
additional value beyond MRI in glioma management. 
 
Outlook-Perspective 
Future clinical studies should consider the use of amino acid PET as an additional 
imaging modality for gliomas complementary to MRI. Standardized technical 
guidelines for PET imaging procedures and recommendations by the EANM / EANO / 
RANO group will be published separately. 
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Table 1: Diagnostic performance of different amino acid tracers compared to conventional and advanced MRI 
 
Clinical Problem MET FET FDOPA 
Differentiation of glioma from non-
neoplastic lesions 
numerous studies 
19
, higher diagnostic 
accuracy than MRI alone 
higher diagnostic accuracy than MRI alone 
11, 12, 18
 
not available for the initial diagnosis 
Glioma grading (including detection 
of anaplastic foci) 
higher diagnostic accuracy than MRI, but still 
limited accuracy due to high overlap between 
WHO grades 
19, 96
 
higher diagnostic accuracy than MRI, in 
particular for dynamic PET 
14, 26, 93
 
high accuracy by combination of dynamic 
FET-PET and diffusion MRI 
97
 
no studies available comparing 
directly PET to MRI; in the pure PET 
studies conflicting results reporting 
high 
38, 98
 and low 
28, 99
 performance  
Delineation of  
glioma extent 
metabolically active tumor larger than 
contrast enhancement in LGG and HGG at 
diagnosis and recurrence 
100, 101
 
 
delineates metabolically active tumor in non-
enhancing anaplastic glioma 
32, 102
 
in newly diagnosed glioblastoma, 
metabolically active tumor larger than CE 
pre- and postoperatively 
46, 103
 
 
in WHO grade II-IV gliomas metabolically 
active tumor larger than rCBV 
104
 
in glioma metabolically active tumor 
larger than rCBV 
105
, ADC 
106
 and 
contrast enhancement 
34, 36
 
Differentiation of glioma recurrence 
from treatment-induced changes 
(e.g., pseudoprogression, 
radionecrosis) 
higher diagnostic accuracy than MRI 
66
 
higher diagnostic accuracy than MRI
 74, 81, 
107
 
higher diagnostic accuracy than MRI 
17, 37, 79, 108
 
Assessment of  
treatment response (including 
pseudoresponse) 
superior to MRI; metabolic response to TMZ 
predictive for survival
 70
 
 
 
superior to MRI; metabolic responses to 
TMZ 
83
, RT 
69, 71
 and BEV 
76, 78
  occurred 
earlier and/or were associated with 
improved survival 
 
superior to MRI; metabolic response 
to BEV 
77
 occurred earlier and was 
predictive for improved survival 
Assessment of prognosis  
in gliomas 
in contrast to pretreatment CE volumes, 
metabolically active tumor volumes are 
prognostic in HGG 
86, 95
 
metabolically active tumor volume is 
prognostic in WHO grade IV glioma 
46
 
 
higher prognostic value of time-activity-
curves in dynamic PET than MRI within 
WHO grade II and WHO grade III-IV glioma 
15, 91, 92
 
 
FET uptake in combination with specific 
superior to MRI in WHO grade II 
glioma; maximum uptake is an 
independent predictor of 
progression 
109
 
MRI findings is prognostic 
94
 for WHO grade 
II glioma 
MET: [
11
C-methyl]-methionine; FET: O-(2-[
18
F]-fluoroethyl)-L-tyrosine; FDOPA: 3,4-dihydroxy-6-[
18
F]-fluoro-L-phenylalanine; MRI: Magnetic resonance imaging; 
PET: positron emission tomography; WHO: World Health Organization; CE: contrast enhancement; rCBV: relative cerebral blood volume; ADC: apparent 
diffusion coefficient; TMZ: temozolomide; RT: radiotherapy; BEV: bevacizumab 
 
Table 2: Overview of histologically validated amino acid PET studies in gliomas 
 
Clinical Problem MET FET FDOPA 
Differentiation of neoplastic from 
non-neoplastic lesions 
stereotactic biopsy 
110
 
 
hot-spot guided resection
 111
 
stereotactic biopsy and hot spot-guided 
resection
 11
 
n.a. 
Differentiation between  
WHO grade II and WHO grade III/IV 
glioma 
in a subset of patients stereotactic biopsy 
112
  stereotactic biopsy 
14, 22, 25
 
in a subset of patients stereotactic 
biopsy and hot spot-guided 
resection 
38
 
Delineation of  
glioma extent 
stereotactic biopsy 
39, 43, 113, 114
 
 
hot-spot guided resection 
101, 115
 
 
stereotactic biopsy 
41, 116
 
 
stereotactic biopsy and hot spot-guided 
resection 
117
 
in a subset of patients hot spot-
guided resection
 36
 
Differentiation of glioma recurrence 
from treatment-induced changes  
(e.g., radionecrosis) 
stereotactic biopsy
 118
 
 
stereotactic biopsy 
119
 
 
stereotactic biopsy and hot spot-guided 
resection
 81, 120
 
in a subset of patients stereotactic 
biopsy 
17, 108
 
Detection of malignant tumor parts in 
MRI findings suggestive for WHO 
grade II glioma 
stereotactic biopsy and hot spot-guided 
resection 
96
 
 
stereotactic biopsy 
26
 
 
stereotactic biopsy and hot spot-guided 
resection 
93
 
n.a. 
Assessment of prognosis  
in untreated gliomas 
histological confirmation of glioma only 
95
 
(local comparison not necessary) 
histological confirmation of glioma only 
15, 91
 
(local comparison not necessary) 
histological confirmation of glioma 
only 
109
 (local comparison not 
necessary) 
MET: [
11
C-methyl]-methionine; FET: O-(2-[
18
F]-fluoroethyl)-L-tyrosine; FDOPA: 3,4-dihydroxy-6-[
18
F]-fluoro-L-phenylalanine; MRI: Magnetic resonance imaging; 
WHO: World Health Organization; n.a.: not available 
 
Resection  
or  
biopsy 
Radiotherapy or 
chemotherapy or 
both  
Maintenance 
therapy 
Suspected 
primary 
glioma on 
MRI 
Follow-up 
Figure 1 
Rationale for initial AA PET: 
• Differentiation neoplastic vs. non-neoplastic tissue 
• Delineation of tumor extent for resection planning 
• „Hot-Spot“ localization for biopsy planning 
• Prognostication 
Rationale for AA PET after surgery: 
• Assessment of resection extent 
• Planning of radiotherapy 
• Baseline AA PET for monitoring of radio(chemo)therapy 
• Prognostication 
Rationale for AA PET within first 12 weeks after radio(chemo)therapy: 
• Diagnosis of treatment-induced changes (e.g., pseudoprogression) versus 
treatment relapse 
• Follow-up AA PET for monitoring of radio(chemo)therapy 
• Baseline AA PET for adjuvant therapy monitoring 
Rationale for AA PET during follow-up: 
• Diagnosis of treatment-induced changes 
(e.g., radionecrosis) versus treatment 
relapse 
• Follow-up AA PET for adjuvant therapy 
monitoring 
• Delineation of tumor extent for resection 
planning 
Indications for amino acid PET 
SUV 
